12:00 AM
 | 
May 28, 2012
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 5/25 cls
Affymax Inc. (NASDAQ:AFFY) MLV Ed Arce Price target Buy 8% $14.07
Arce raised his target to $21 from $12 after Affymax and partner Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) launched once-monthly Omontys peginesatide in the U.S. to treat anemia in chronic kidney disease (CKD) patients who are on dialysis (see BioCentury, April 30). He believes the net overall cost of Omontys will be lower than anemia drug Epogen epoetin alfa from Amgen Inc. (NASDAQ:AMGN), and that nephrologists will view Omontys' label as comparable to Epogen in terms of efficacy and risk. Arce also anticipates an EU launch of the synthetic peptide-based erythropoiesis-stimulating agent (ESA) in early 2013.
Dendreon Corp. (NASDAQ:DNDN) Jefferies Biren Amin New Underperform -2% $7.11
Biren also set a $5 target. He believes Dendreon's Provenge sipuleucel-T is likely to be a "distant third...

Read the full 955 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >